Ebola, not bureaucracy, is what many Africans say should be on trial. Yet criticism has quickly locked onto the continent’s largest health agency, accused of mishandling its early response while the virus again stalks fragile systems and exhausted clinicians.
To African officials, the speed of that judgment looks less like oversight and more like habit. They point to past Ebola waves, when case fatality ratios dwarfed those of many respiratory outbreaks elsewhere, yet triggered slower funding, leaner stockpiles of personal protective equipment, and thinner investment in genomic surveillance or cold-chain logistics. When rich states faced fewer deaths from other pathogens, emergency authorizations, indemnity clauses, and blank-cheque procurement arrived almost overnight; for African outbreaks, the same playbook turns tentative and conditional.
What stings, they argue, is not scrutiny but selectivity. The agency now under fire was created to assert regulatory autonomy, coordinate incident management systems, and reduce dependence on external rapid-response teams, yet it is being judged against standards that major Western institutions themselves rarely met during their own surges. Behind the anger lies a blunt question whispered in clinics and ministries alike: is this about epidemiology and infection prevention, or about who is allowed to fail in public without having their entire system written off.
